Whitehawk Therapeutics Depreciation & Amortization Growth & History (WHWK)
Whitehawk Therapeutics's depreciation and amortization was $79,000 for fiscal 2025.
View full Whitehawk Therapeutics company overviewWhitehawk Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $79,000 | −$114,000 | −59.07% |
| 2024 | 2024-12-31 | $193,000 | $24,000 | +14.20% |
| 2023 | 2023-12-31 | $169,000 | $10,000 | +6.29% |
| 2022 | 2022-12-31 | $159,000 | $54,000 | +51.43% |
| 2021 | 2021-12-31 | $105,000 | $96,000 | +1066.67% |
| 2020 | 2020-12-31 | $9,000 | −$67,501 | −88.24% |
| 2019 | 2019-12-31 | $76,501 | $29,815 | +63.86% |
| 2018 | 2018-12-31 | $46,686 | −$4,582 | −8.94% |
| 2017 | 2017-12-31 | $51,268 | −$18,405 | −26.42% |
| 2016 | 2016-12-31 | $69,673 | — | — |
Whitehawk Therapeutics quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1,000 | −$14,300 | −93.46% |
| Q1 2026 | 2026-03-31 | $1,000 | −$56,000 | −98.25% |
| Q4 2025 | 2025-12-31 | $1,000 | — | — |
| Q3 2025 | 2025-09-30 | $5,600 | −$41,100 | −88.01% |
| Q2 2025 | 2025-06-30 | $15,300 | −$34,300 | −69.15% |
| Q1 2025 | 2025-03-31 | $57,000 | $7,000 | +14.00% |
| Q3 2024 | 2024-09-30 | $46,700 | $2,700 | +6.14% |
| Q2 2024 | 2024-06-30 | $49,600 | $6,600 | +15.35% |
| Q1 2024 | 2024-03-31 | $50,000 | $12,000 | +31.58% |
| Q3 2023 | 2023-09-30 | $44,000 | $32,000 | +266.67% |
| Q2 2023 | 2023-06-30 | $43,000 | $16,000 | +59.26% |
| Q1 2023 | 2023-03-31 | $38,000 | −$36,000 | −48.65% |
| Q3 2022 | 2022-09-30 | $12,000 | −$17,000 | −58.62% |
| Q2 2022 | 2022-06-30 | $27,000 | $25,000 | +1250.00% |
| Q1 2022 | 2022-03-31 | $74,000 | $72,000 | +3600.00% |
| Q3 2021 | 2021-09-30 | $29,000 | $13,282 | +84.50% |
| Q2 2021 | 2021-06-30 | $2,000 | −$13,067 | −86.73% |
| Q1 2021 | 2021-03-31 | $2,000 | −$13,102 | −86.76% |
| Q3 2020 | 2020-09-30 | $15,718 | −$4,471 | −22.15% |
| Q2 2020 | 2020-06-30 | $15,067 | −$5,446 | −26.55% |
| Q1 2020 | 2020-03-31 | $15,102 | $2,112 | +16.26% |
| Q3 2019 | 2019-09-30 | $20,189 | $8,542 | +73.34% |
| Q2 2019 | 2019-06-30 | $20,513 | $9,378 | +84.22% |
| Q1 2019 | 2019-03-31 | $12,990 | $460 | +3.67% |
| Q3 2018 | 2018-09-30 | $11,647 | −$505 | −4.16% |
| Q2 2018 | 2018-06-30 | $11,135 | −$2,326 | −17.28% |
| Q1 2018 | 2018-03-31 | $12,530 | −$1,126 | −8.25% |
| Q3 2017 | 2017-09-30 | $12,152 | −$3,101 | −20.33% |
| Q2 2017 | 2017-06-30 | $13,461 | −$8,045 | −37.41% |
| Q1 2017 | 2017-03-31 | $13,656 | −$2,829 | −17.16% |
| Q3 2016 | 2016-09-30 | $15,253 | — | — |
| Q2 2016 | 2016-06-30 | $21,506 | — | — |
| Q1 2016 | 2016-03-31 | $16,485 | — | — |
Whitehawk Therapeutics depreciation and amortization trends
Over the last five fiscal years, Whitehawk Therapeutics's depreciation and amortization increased from $9,000 to $79,000, a change of $70,000. The latest reported quarter, Q2 2026, shows $1,000.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Whitehawk Therapeutics source filings ↗